Inhale Therapeutics

Inhale Therapeutics is a private, R&D-focused company leveraging its proprietary Reservoir Dry Powder Inhaler (RDPI®) platform to deliver a broad range of drugs, from small molecules to proteins. With over 35 years of collective expertise in inhaled product development, the company offers end-to-end services from formulation and device combination through scale-up and regulatory dossier preparation. It positions itself as a development and manufacturing partner for novel chemical entities, novel therapeutic entities, and generic drug products, aiming to disrupt the market with technically and economically feasible solutions.

Proprietary Reservoir Dry Powder Inhaler (RDPI®) platform designed to deliver a broad range of drugs (small molecules to proteins) with high lung delivery efficiency. Services include combined formulation and device development, scale-up, and regulatory support.

Competes with large pharmaceutical companies with in-house device divisions (e.g., GSK, AstraZeneca), established generic inhaler manufacturers (e.g., Viatris, Cipla), and specialized drug delivery/CDMO companies (e.g., Catalent, Lonza's inhalation services). Differentiation is based on claimed cost-effectiveness and technical expertise.